PharmaFocus Today – Page 119 – media

CanSino’s Infant DTcP Vaccine Included in Priority Review

On February 7, CanSino Biologics announced that information on the website of the Center for Drug Evaluation under the National Medical Products Administration indicates that its Adsorbed Acellular Pertussis, Diphtheria, and Tetanus Combined Vaccine for Infants (hereinafter referred to as “Infant DTcP”) has been officially included in the priority review category. CanSino explained that the currently available pertussis-diphtheria-tetanus (DTP) vaccines on the domestic market use a co-purification process for pertussis antigens during manufacturing. In contrast, CanSino’s Infant DTcP is a component-based vaccine, in which each pertussis antigen is individually purified and then formulated in precise proportions. This process ensures batch-to-batch consistency and enhances the overall stability of the product’s quality. As of now, no domestically developed component-based DTP vaccines have been approved for sale in China. CanSino’s Infant DTcP is positioned as a domestic alternative to imported vaccines. Furthermore, the development of this vaccine lays the foundation for future research ...
- Source: drugdu
- 273
- February 10, 2025
Minhai Biotechnology’s Bivalent and Quadrivalent Inactivated Enterovirus Vaccines (Vero Cell) Approved for Clinical Trials

On February 7, Kangtai Biological issued an announcement stating that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd. (hereinafter referred to as “Minhai Biotechnology”), has received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration (NMPA) for its bivalent inactivated enterovirus vaccine (Vero cell) and quadrivalent inactivated enterovirus vaccine (Vero cell). The company will promptly initiate related clinical trials in accordance with the requirements of the approval notice. The bivalent inactivated enterovirus vaccine (Vero cell) is intended for individuals aged 6 months to 71 months who are susceptible to EV-A71 and CV-A16. It stimulates the body to produce immunity against EV-A71 and CV-A16, and is used to prevent infectious diseases such as hand, foot, and mouth disease (HFMD) caused by enterovirus EV-A71 and CV-A16 infections. The quadrivalent inactivated enterovirus vaccine (Vero cell) is suitable for individuals aged 6 months to 71 months who are susceptible to EV-A71, ...
- Source: drugdu
- 267
- February 10, 2025
How DeepSeek Helps You Succeed Efficiently

In recent years, the application of artificial intelligence has been transforming industries at an unprecedented pace. As a leading AI-powered Q&A assistant, DeepSeek has quickly become a trusted partner for professionals in global trade. Particularly in the complex field of pharmaceutical trade, DeepSeek provides a range of practical tools to help businesses accurately target markets, enhance efficiency, and mitigate risks. As a global leader in cross-border pharma trade, Drugdu.com has explored ways to integrate DeepSeek’s capabilities with industry needs, delivering more efficient solutions to its users. Here’s how DeepSeek can empower your pharma trade business: Accurate Market Insights: AI as Your Detective Quickly Identify Customers and Markets Wondering which Southeast Asian country has the highest demand for raw pharmaceutical ingredients? DeepSeek uses big data analysis to provide swift, accurate answers and even generates visual reports, saving you time compared to traditional customs data checks. Monitor Competitors in Real-Time With ...
- Source: drugdu
- 478
- February 10, 2025
AI DeepSeek Drugdu Pharma Trade
Analysis Report on Import and Export of Medical Devices in China

This report is based on the import and export data of China Customs, and conducts multidimensional analysis from the overall trend of medical device import and export, trade categories, trading partners, trading provinces and cities, aiming to objectively evaluate the trend and market pattern of China’s medical device import and export trade, and provide certain data references for relevant enterprise project evaluation, market research, channel expansion, etc. The relevant data are all sourced from the global medical device big data service platform – Yaozhi Medical Device Data, under the umbrella of Yaozhi Network. If you need detailed data in the report, please go to Yaozhi Medical Equipment Data for more information. Overall analysis Overall, compared to last year, China’s import and export trade volume has shown a comprehensive growth trend. From January to December 2024, overall data shows that in terms of exports, the Asian market is the largest export ...
- Source: drugdu
- 777
- February 7, 2025
Starting from February 1st, the settlement method for centralized procurement consumables has changed

Hunan will implement a new settlement method for centralized procurement consumables, with artificial crystals as the first batch of products. Starting from February 1st, the settlement method will be changed Recently, the Hunan Provincial Medical Security Bureau issued a notice on the direct settlement of medical insurance fund payments for selected medical consumables in centralized quantity procurement (hereinafter referred to as the “Notice”), requiring direct settlement of medical insurance fund payments for selected consumables products in centralized procurement to be carried out from February 1, 2025. The document on which the “Notice” is based is the “Notice on Implementing Direct Settlement of Medical Insurance Funds for Centralized Procurement of Selected Products’ Medical Payment” (Xiang Medical Insurance Fa [2023] No. 36). The Notice specifies that from February 1st, direct settlement of medical insurance funds for selected consumables products through centralized procurement will be carried out. The first batch of consumables selected ...
- Source: drugdu
- 256
- February 7, 2025
Haisike has been approved to conduct clinical trials of the innovative drug HSK39004

On February 5, Haisike (002653) issued an announcement that its subsidiaries Tibet Haisike Pharmaceutical Co., Ltd. and Sichuan Haisike Pharmaceutical Co., Ltd. recently received the “Notice of Approval for Drug Clinical Trials” issued by the State Drug Administration, approving the innovative drug HSK39004 inhalation powder spray developed by them to conduct clinical trials. The drug is mainly used to treat chronic obstructive pulmonary disease and meets the relevant requirements for drug registration. HSK39004 is a targeted small molecule inhibitor independently developed by the company. Preclinical studies have shown that it has significant effects on airway relaxation and anti-inflammation, and has good safety and great development potential. According to the drug registration classification regulations, the drug is classified as Class 1 chemical drug. Although the project has good prospects, the company also reminds investors that the research and development cycle of innovative drugs is long and the risk is high, and ...
- Source: drugdu
- 280
- February 7, 2025
Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released

Follow the incremental policy and grasp the incremental rhythm. At this stage and for a long time in the future, innovative drugs are the most clear direction of incremental policy support. We continue to be optimistic about high-quality innovative pharmaceutical companies and transformation companies that have achieved results. Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released. The new version of the medical insurance catalogue will be implemented from January 2025, and many newly included blockbuster innovative drugs will speed up their entry into hospitals under the promotion of the implementation details. The 2025 medical insurance negotiations will be reported in advance on April 1, and the medical insurance negotiations will end in September, which will help the newly approved products to be included in the medical insurance faster. The first version of the Class C catalog is expected ...
- Source: drugdu
- 395
- February 7, 2025
Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market

On February 4, Merck announced its fourth quarter financial report for 2024 and its full-year performance last year. Of the $64.2 billion in sales for the year, its PD-1 monoclonal antibody product pembrolizumab (trade name Keytruda, commonly known as “Keytruda”) accounted for nearly half, with sales of $29.5 billion. Merck also announced that it would suspend shipments of HPV vaccine products Gardasil/Gardasil 9 to the Chinese market from February this year, and this decision will last at least until the middle of this year. Merck China said that this decision was mainly affected by the overall market environment, weak consumer demand and high channel inventory; it also maintains full confidence in the potential of the Chinese market. Suspending shipments to the Chinese market from this month At the same time as announcing its financial report, Merck announced a highly anticipated decision, namely, from February this year, it will suspend shipments ...
- Source: drugdu
- 240
- February 7, 2025
The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU

On February 5, Fosun Pharma announced that the marketing authorization application (MAA) of slulizumab injection (i.e., anti-PD-1 monoclonal antibody) independently developed by the holding subsidiary Shanghai Fuhong Henlius Biotech Co., Ltd. and its holding subsidiaries (collectively referred to as “Fuhong Henlius”) for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) was recently approved by the European Commission (i.e., the European Commission). Accordingly, the drug has obtained centralized marketing authorization in all EU member states and Iceland, Liechtenstein and Norway (European Economic Area countries respectively), and has become the first anti-PD-1 monoclonal antibody approved by the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC). https://finance.eastmoney.com/a/202502063311927270.html
- Source: drugdu
- 262
- February 7, 2025
Nepal launches national HPV vaccination program, expected to benefit more than 1.68 million girls

The Nepali government officially launched the HPV vaccination program nationwide on the 4th, and it is expected to vaccinate more than 1.68 million girls aged 10 to 14 to prevent cervical cancer and other related diseases. Nepali Prime Minister Oli attended the launch ceremony in the capital Kathmandu on the same day and presented vaccination materials to health workers. The vaccination program is led by the Ministry of Health and Population of Nepal and supported by the Global Vaccine Alliance (GAVI). It will be carried out nationwide from February 4 to 18, 2025. It is reported that a total of 18,900 schools in Nepal have been designated as vaccination centers, and another 8,200 medical institutions will provide vaccination services to the public. The Ministry of Health and Population of Nepal said that cervical cancer is the second most common cancer among women in Nepal and the leading cause of cancer ...
- Source: drugdu
- 304
- February 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.